GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Structure Therapeutics Inc (NAS:GPCR) » Definitions » Price-to-Operating-Cash-Flow

Structure Therapeutics (Structure Therapeutics) Price-to-Operating-Cash-Flow : (As of May. 24, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Structure Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-05-24), Structure Therapeutics's share price is $38.32. Structure Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.18. Hence, Structure Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Structure Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

GPCR's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 26.455
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Structure Therapeutics's Cash Flow from Operations per share for the three months ended in Mar. 2024 was $-0.73. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.18.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -56.00% per year.

During the past 4 years, Structure Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was -56.00% per year. The lowest was -56.00% per year. And the median was -56.00% per year.


Structure Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Structure Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Structure Therapeutics Price-to-Operating-Cash-Flow Chart

Structure Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
- - - -

Structure Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Structure Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Structure Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Structure Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Structure Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Structure Therapeutics's Price-to-Operating-Cash-Flow falls into.



Structure Therapeutics Price-to-Operating-Cash-Flow Calculation

Structure Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=38.32/-2.18
=

Structure Therapeutics's Share Price of today is $38.32.
Structure Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.18.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Structure Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Structure Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Structure Therapeutics (Structure Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 223, South San Francisco, CA, USA, 94080
Structure Therapeutics Inc is a clinical-stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
Executives
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Melita Sun Jung officer: Chief Business Officer C/O STRUCTURE THERAPEUTICS INC., SOUTH SAN FRANCISCO CA 94080
Yingli Ma officer: Chief Technology Officer C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD., SUITE 223, SOUTH SAN FRANCISCO CA 94080
Joanne Waldstreicher director C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD, SUITE 223, SOUTH SAN FRANCISCO CA 94080
Jun Yoon officer: Chief Financial Officer C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD, SUITE 223, SOUTH SAN FRANCISCO CA 94080

Structure Therapeutics (Structure Therapeutics) Headlines